Disease · MONDO_0003219
Comparisons in its trials80
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 80
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Tislelizumab + Chemotherapy vs Placebo + Chemotherapy: deaths from any cause | 397 of 501 | 431 of 496 | 997 | NCT03777657 | Trial comparisons |
| Tislelizumab + Chemotherapy vs Placebo + Chemotherapy: serious adverse events | 211 of 498 | 179 of 494 | 992 | NCT03777657 | Trial comparisons |
| Cetuximab Plus Capecitabine Plus Cisplatin vs Capecitabine Plus Cisplatin: Safety - Number of Participants With Adverse Events (AEs) | 446 of 446 | 432 of 436 | 882 | NCT00678535 | Trial comparisons |
| Cetuximab Plus Capecitabine Plus Cisplatin vs Capecitabine Plus Cisplatin: serious adverse events | 239 of 446 | 194 of 436 | 882 | NCT00678535 | Trial comparisons |
| Napabucasin + Paclitaxel vs Placebo + Paclitaxel: Number of Patients With Adverse Events | 352 of 357 | 338 of 350 | 707 | NCT02178956 | Trial comparisons |
| Napabucasin + Paclitaxel vs Placebo + Paclitaxel: deaths from any cause | 286 of 357 | 275 of 350 | 707 | NCT02178956 | Trial comparisons |
| Napabucasin + Paclitaxel vs Placebo + Paclitaxel: serious adverse events | 125 of 357 | 101 of 350 | 707 | NCT02178956 | Trial comparisons |
| Ramucirumab and Paclitaxel vs Placebo and Paclitaxel: serious adverse events | 161 of 327 | 146 of 329 | 656 | NCT01170663 | Trial comparisons |
| Ramucirumab + Cisplatin + Capecitabine vs Placebo + Cisplatin + Capecitabine: Number of Participants With Anti-Ramucirumab Antibodies | 4 of 323 | 5 of 315 | 638 | NCT02314117 | Trial comparisons |
| LY3009806+Capecitabine+Cisplatin vs Placebo+Capecitabine+Cisplatin: serious adverse events | 161 of 323 | 150 of 315 | 638 | NCT02314117 | Trial comparisons |
| Pembrolizumab vs Chemotherapy: Number of Participants Experiencing an Adverse Event (AE) | 301 of 314 | 288 of 296 | 610 | NCT02564263 | Trial comparisons |
| Pembrolizumab vs Chemotherapy: Number of Participants Discontinuing Study Treatment Due an Adverse Event (AE) | 40 of 314 | 42 of 296 | 610 | NCT02564263 | Trial comparisons |
| Napabucasin + Paclitaxel vs Placebo + Paclitaxel: Objective Response Rate | 16 of 289 | 18 of 283 | 572 | NCT02178956 | Trial comparisons |
| Napabucasin + Paclitaxel vs Placebo + Paclitaxel: Disease Control Rate | 55 of 289 | 58 of 283 | 572 | NCT02178956 | Trial comparisons |
| mFOLFOX6 + Zolbetuximab vs mFOLFOX6+ Placebo: Number of Participants With Treatment Emergent Adverse Events (TEAEs) | 278 of 279 | 277 of 278 | 557 | NCT03504397 | Trial comparisons |
| Surgery + Adjuvant Chemotherapy (SC) vs Neoadjuvant Chemotherapy +Surgery +Adjuvant Chemotherapy (CSC): deaths from any cause | 91 of 264 | 78 of 266 | 530 | NCT01515748 | Trial comparisons |
| CAPOX+ Zolbetuximab vs CAPOX+ Placebo: Number of Participants With Treatment Emergent Adverse Events (TEAEs) | 251 of 254 | 244 of 249 | 503 | NCT03653507 | Trial comparisons |
| CapeOx Plus Lapatinib vs CapeOx Plus Placebo: Percentage of Participants With Clinical Benefit (CB) | 199 of 249 | 188 of 238 | 487 | NCT00680901 | Trial comparisons |
| CapeOx Plus Lapatinib vs CapeOx Plus Placebo: Percentage of Participants With a Confirmed Complete Response (CR) or a Partial Response (PR) | 131 of 249 | 94 of 238 | 487 | NCT00680901 | Trial comparisons |
| 8 mg/kg Ramucirumab + 80 mg/m² Paclitaxel vs Placebo + 80 mg/m² Paclitaxel: deaths from any cause | 246 of 294 | 123 of 146 | 440 | NCT02898077 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0003219/comparisons